Moderna to Build Vaccine-Manufacturing Plant in Africa

October 7, 2021

(Wall Street Journal) – Moderna Inc. MRNA 2.29% plans to spend up to $500 million to build a new manufacturing plant in Africa to supply doses of its Covid-19 vaccine and potential additional vaccines to a continent that has grappled with a shortage. The Cambridge, Mass., drug company said Thursday it will build a state-of-the-art facility that could produce up to 500 million doses annually of vaccines, using its gene-based technology, known as messenger RNA. Moderna’s only current product is its Covid-19 vaccine, but the company is developing other vaccines against Zika, influenza, cytomegalovirus and other pathogens that could be made at the plant and meet demand in Africa. (Read Full Article)